---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-025891"
form_type: "8-K"
ticker: "CELC"
cik: "0001603454"
company_name: "Celcuity Inc."
filed_at: "2022-09-14T23:59:59+00:00"
generated_at: "2026-06-23T09:43:16.914076+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Celcuity appoints Dr. Polly Murphy to Board; reduces warrant shares to 70K

## Summary
- Warrant amended: shares reduced from 138,000 to 70,000; exercise period extended to Sept 19, 2025.
- Board expanded to 7 directors; Dr. Polly Murphy elected as independent director, effective immediately.
- Dr. Murphy brings 20+ years of pharma biz dev experience including 12 years at Pfizer; currently CBO of UroGen Pharma.
- Dr. Murphy granted options: 16,300 shares vesting by 2023 annual meeting or April 30, 2023; plus 10,000 shares vesting over 4 years.
- Company expects to dose first patient in Phase 3 gedatolisib study for HR+/HER2- breast cancer in next few months.

## SEC filing metadata
- accession: 0001493152-22-025891
- form_type: 8-K
- ticker: CELC
- cik: 0001603454
- company_name: Celcuity Inc.
- filed_at: 2022-09-14T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.03, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1603454/000149315222025891/0001493152-22-025891-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1603454/000149315222025891/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-025891
- JSON: https://secwatch.observer/filing/0001493152-22-025891.json
- Plain text: https://secwatch.observer/filing/0001493152-22-025891.txt

## Key facts
- Executive change
  Polly Murphy was elected as Director at Celcuity Inc..
  - Action: elected
  - Role: Director
  source text: On September 12, 2022, the Board of Directors (the “Board”) of the Company, voted to increase the size of the Board from six members to seven members and to elect Polly Murphy, D.V.M., Ph.D. as a new director to fill the resulting vacancy.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1603454/000149315222025891/0001493152-22-025891-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.